Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial

Authors: Xu, Bushu; Pan, Qiuzhong; Li, Shining; Peng, Ruiqing; Zhang, Lihong; Li, Hui; Yu, Shiying; Zhang, Xing

Source journal: BMC medicine (2026-08-25)

DOI: 10.1186/s12916-026-05154-7

Abstract

BACKGROUND: Patients with advanced, treatment-refractory sarcoma face a poor prognosis and limited options following failure of standard therapies. This study evaluated the efficacy and safety of surufatinib, a novel inhibitor targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), in patients with advanced sarcoma who had failed standard therapy. METHODS: In this multicenter, single-arm, phase 2 trial, patients with unresectable or metastatic sarcoma who had received prior treatment were enrolled and received surufatinib 300 mg once daily. The primary endpoint was the 12-week progression-free rate (PFR(12w)). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). RESULTS: As of September 30, 2025, the median follow-up was 27.5 months among 47 enrolled patients; 46.8% had received >/= 2 prior lines of therapy. In 45 evaluable patients, the PFR(12w) was 71.1%. The ORR was 11.1%, including one complete response in a patient with angiosarcoma, and the DCR was 86.7%. Median PFS was 4.3 months, with significantly longer PFS when surufatinib was used as second-line therapy compared with later lines (5.7 vs. 2.8 months; p /= 3 treatment-related adverse events occurred in 29.8% of patients. CONCLUSIONS: These findings indicate that surufatinib has preliminary antitumor activity and a manageable safety profile in advanced sarcoma, even after prior anti-angiogenic therapy. The encouraging efficacy observed in the second-line setting and in non-uterine leiomyosarcoma provides a rationale for continued clinical development. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05106777. CLINICA TRIAL REGISTRY: ClinicalTrials.gov ( http://www. CLINICALTRIALS: gov/ ).

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.